Splenic function and IgM-memory B cells in Crohn's disease patients treated with infliximab.

Abstract:

BACKGROUND:Under experimental chronic inflammation, tumor necrosis factor (TNF)-alpha plays a role in damaging spleen marginal zone. This latter has a crucial function in mounting B cell-dependent immune responses against infections by encapsulated bacteria. In Crohn's disease (CD), a chronic inflammatory disorder where TNF-alpha is centrally involved, impaired splenic function may increase the susceptibility to bacterial infections. On this basis, we aimed to investigate the influence of anti-TNF therapy on splenic function in CD patients. METHODS:Peripheral blood samples were obtained from 15 CD patients before and after treatment with infliximab administered at weeks 0, 2, and 6 at a dose of 5 mg/kg. Counting of erythrocytes with membrane abnormalities (pitted red cells) was used as an indicator of splenic function. Multicolor flow cytometry was performed to analyze circulating B cells. RESULTS:A substantial clinical improvement in 10 of the 15 CD patients was associated with a significant reduction of pitted red cells (from median 6.0% to 3.6%; P < 0.01) after 10 weeks of treatment. In responder patients the improvement of splenic function was accompanied by a parallel increase of circulating IgM-memory B cells (from median 6.9% to 13.3%; P < 0.005). Splenic function was not ameliorated in nonresponder patients. CONCLUSIONS:Splenic function improved in CD patients who responded to infliximab and was accompanied by a concomitant restoration of the IgM-memory B cell pool responsible for the protection against encapsulated bacteria. Restoration of splenic function after infliximab treatment is intriguing and requires further investigation.

journal_name

Inflamm Bowel Dis

authors

Di Sabatino A,Rosado MM,Cazzola P,Biancheri P,Tinozzi FP,Laera MR,Cantoro L,Vanoli A,Carsetti R,Corazza GR

doi

10.1002/ibd.20374

subject

Has Abstract

pub_date

2008-05-01 00:00:00

pages

591-6

issue

5

eissn

1078-0998

issn

1536-4844

journal_volume

14

pub_type

杂志文章
  • Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics.

    abstract:BACKGROUND:Data from CHARM, a 56-week, randomized controlled trial of adalimumab for patients with moderately to severely active Crohn's disease (CD), were used to evaluate outcomes of adalimumab dosage adjustment. METHODS:Patients randomized to blinded adalimumab 40 mg every other week (EOW) in CHARM were the focus o...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/ibd.21328

    authors: Sandborn WJ,Colombel JF,Schreiber S,Plevy SE,Pollack PF,Robinson AM,Chao J,Mulani P

    更新日期:2011-01-01 00:00:00

  • Serum adalimumab concentration and clinical remission in patients with Crohn's disease.

    abstract:BACKGROUND:Drug concentration monitoring may be useful to guide therapeutic adjustments for anti-tumor necrosis factor agents in Crohn's disease. The relationship between serum adalimumab concentrations and clinical outcomes was assessed using data from CLinical Assessment of Adalimumab Safety and Efficacy Studied as I...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/MIB.0b013e3182813242

    authors: Chiu YL,Rubin DT,Vermeire S,Louis E,Robinson AM,Lomax KG,Pollack PF,Paulson SK

    更新日期:2013-05-01 00:00:00

  • Biomarker-Based Models Outperform Patient-Reported Scores in Predicting Endoscopic Inflammatory Disease Activity.

    abstract:Background:The Crohn's Disease Activity Index (CDAI), a scoring index including patient-reported outcomes (PROs), has known limitations for measuring intestinal inflammatory disease burden. Noninvasive markers of inflammation could prove more accurate than PROs; thus, regulatory authorities are exploring the use of PRO...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1093/ibd/izx018

    authors: Morris MW,Stewart SA,Heisler C,Sandborn WJ,Loftus EV,Zello GA,Fowler SA,Jones JL

    更新日期:2018-01-18 00:00:00

  • Segmental Resection versus Total Proctocolectomy for Crohn's Colitis: What is the Best Operation in the Setting of Medically Refractory Disease or Dysplasia?

    abstract::Crohn's disease (CD) may affect any part of the gastrointestinal tract. When isolated to the colon, and patients become medically refractory, there are several surgical options - segmental resection, subtotal colectomy with ileorectal anastomosis, or a total proctocolectomy and end ileostomy. Unfortunately, surgery do...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1093/ibd/izx064

    authors: Lightner AL

    更新日期:2018-02-15 00:00:00

  • Genome-wide association scans identify multiple confirmed susceptibility loci for Crohn's disease: lessons for study design.

    abstract::The last 12 months have seen unprecedented progress in identifying the susceptibility genes that predispose to common disease in general and Crohn's disease in particular. Success has derived from the new technique of genome-wide association scanning in large panels of cases and controls. This has itself been made pos...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.20239

    authors: Tremelling M,Parkes M

    更新日期:2007-12-01 00:00:00

  • The IBD-F Patient Self-Assessment Scale Accurately Depicts the Level of Fatigue and Predicts a Negative Effect on the Quality of Life of Patients With IBD in Clinical Remission.

    abstract:BACKGROUND:Fatigue is highly prevalent among patients with inflammatory bowel disease (IBD) and may have an unfavorable impact on quality of life (QoL). The IBD-Fatigue scale (with components SCORE1 and SCORE2) is a recently developed disease-specific questionnaire. We sought to validate a Greek version of IBD-F and us...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izaa201

    authors: Varbobitis I,Kokkotis G,Gizis M,Perlepe N,Laoudi E,Bletsa M,Bekiari D,Koutsounas I,Kounadis G,Xourafas V,Lagou S,Kolios G,Papakonstantinou I,Bamias G

    更新日期:2020-08-07 00:00:00

  • Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse.

    abstract::: Primary nonresponse and primary nonremission are important limitations of tumor necrosis factor (TNF) antagonists, occurring in 10% to 40% and 50% to 80% of patients with inflammatory bowel disease, respectively. The magnitude of primary nonresponse differs between phase III clinical trials and cohort studies, indic...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000202

    authors: Papamichael K,Gils A,Rutgeerts P,Levesque BG,Vermeire S,Sandborn WJ,Vande Casteele N

    更新日期:2015-01-01 00:00:00

  • Faecalibacterium prausnitzii Produces Butyrate to Maintain Th17/Treg Balance and to Ameliorate Colorectal Colitis by Inhibiting Histone Deacetylase 1.

    abstract:BACKGROUND:Inflammatory bowel disease (IBD)-associated dysbiosis is characterized by a loss of Faecalibacterium prausnitzii, whose supernatant exerts an anti-inflammatory effect. However, the anti-inflammatory substances in F. prausnitzii supernatant and the mechanism in ameliorating colitis in IBD have not yet been fu...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy182

    authors: Zhou L,Zhang M,Wang Y,Dorfman RG,Liu H,Yu T,Chen X,Tang D,Xu L,Yin Y,Pan Y,Zhou Q,Zhou Y,Yu C

    更新日期:2018-08-16 00:00:00

  • Predictors of fibrostenotic Crohn's disease.

    abstract::Intestinal fibrosis is a common and serious complication of Crohn's disease (CD) and as it can occur at any time during the disease course, it is crucial to identify patients at risk. The aim is not only to understand the pathophysiology of fibrogenesis but to be able to accurately inform subjects about their disease ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.21627

    authors: Rieder F,Lawrance IC,Leite A,Sans M

    更新日期:2011-09-01 00:00:00

  • Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.

    abstract:BACKGROUND:The aim of this study was to assess the clinical benefit and tolerability of adalimumab, a fully human monoclonal antibody to tumor necrosis factor (TNF), in patients with ulcerative colitis (UC). METHODS:Patients with active UC, including those who had lost response or developed intolerance to the chimeric...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20924

    authors: Afif W,Leighton JA,Hanauer SB,Loftus EV Jr,Faubion WA,Pardi DS,Tremaine WJ,Kane SV,Bruining DH,Cohen RD,Rubin DT,Hanson KA,Sandborn WJ

    更新日期:2009-09-01 00:00:00

  • Targeted inhibition of heat shock protein 90 suppresses tumor necrosis factor-α and ameliorates murine intestinal inflammation.

    abstract::Inflammatory bowel diseases are chronic intestinal inflammatory diseases thought to reflect a dysregulated immune response. Although antibody-based inhibition of tumor necrosis factor-α (TNF-α) has provided relief to many inflammatory bowel diseases patients, these therapies are either ineffective in a patient subset ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/01.MIB.0000442839.28664.75

    authors: Collins CB,Strassheim D,Aherne CM,Yeckes AR,Jedlicka P,de Zoeten EF

    更新日期:2014-04-01 00:00:00

  • Site organization and management.

    abstract::The principal investigator is responsible for everything involved in the conduct of a clinical research study. Prior to the initiation of any clinical trial, an investigator must become acquainted with the material requirements, personnel needs, and best practices involved in the conduct of the trial. Commitment to a ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/01.mib.0000184848.61687.52

    authors: Wolf DC,Katz S,Safdi MA,Sandler RS,Lewis JD

    更新日期:2005-11-01 00:00:00

  • Impact of timing and duration of thiopurine treatment on first perianal surgery in Crohn's disease: UK population-based study (1995-2009).

    abstract:BACKGROUND:The impact of thiopurine (TP) use on perianal surgery is uncertain. Our aim was to determine trends in perianal surgery and the impact of timing and duration of TPs on the risk of first perianal surgery. METHODS:We identified a population-based cohort of incident cases of Crohn's disease between 1995 and 20...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000290

    authors: Chhaya V,Saxena S,Cecil E,Subramanian V,Curcin V,Majeed A,Pollok RC

    更新日期:2015-02-01 00:00:00

  • Body Mass Index, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohn's Disease.

    abstract:BACKGROUND:Obesity is associated with systemic and intestine-specific inflammation and alterations in gut microbiota, which in turn impact mucosal immunity. Nonetheless, a specific role of obesity and its interaction with genetics in the progression of Crohn's disease (CD) is unclear. METHODS:We conducted a cross-sect...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000498

    authors: Pringle PL,Stewart KO,Peloquin JM,Sturgeon HC,Nguyen D,Sauk J,Garber JJ,Yajnik V,Ananthakrishnan AN,Chan AT,Xavier RJ,Khalili H

    更新日期:2015-10-01 00:00:00

  • FcRL3 gene promoter variant is associated with peripheral arthritis in Crohn's disease.

    abstract:BACKGROUND:The mechanisms responsible for the pathogenesis of peripheral arthropathies (PA) in Crohn's disease (CD) are largely unknown, although many studies indicate that genetic and environmental factors are likely to contribute to risk. METHODS:Because variants in the Fc receptor-like 3 (FcRL3) gene have recently ...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章

    doi:10.1002/ibd.20895

    authors: Mendoza JL,Lana R,Martin MC,de la Concha EG,Urcelay E,Diaz-Rubio M,Abreu MT,Mitchell AA

    更新日期:2009-09-01 00:00:00

  • Pericarditis complicating ulcerative colitis.

    abstract::: Pericarditis occurs rarely in association with inflammatory bowel disease. Because life-threatening complications may occur, pericarditis should be suspected in patients who present with chest symptoms. We report the case of a 28-year-old patient with ulcerative colitis who presented with pericarditis during an acti...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:

    authors: Hinterreiter M,Allinger S,Punzengruber C,Knoflach P

    更新日期:1995-10-01 00:00:00

  • Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease.

    abstract:BACKGROUND:Inflammatory bowel disease (IBD) affects people during their prime reproductive years. The thiopurines (6-mercaptopurine and azathioprine), commonly used for induction and maintenance of remission, are U.S. Food and Drug Administration (FDA) pregnancy category D, raising concern for fetal risk. We performed ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.22948

    authors: Akbari M,Shah S,Velayos FS,Mahadevan U,Cheifetz AS

    更新日期:2013-01-01 00:00:00

  • Role of immunohistochemical markers in predicting progression of dysplasia to advanced neoplasia in patients with ulcerative colitis.

    abstract:BACKGROUND:Although dysplasia is thought to be the precursor lesion in the development of colitis-associated colorectal cancer (CRC), a significant proportion of patients with ulcerative colitis (UC) and low-grade (LGD) or indefinite (IND) dysplasia remain cancer-free during endoscopic follow-up. There is a need for bi...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21722

    authors: van Schaik FD,Oldenburg B,Offerhaus GJ,Schipper ME,Vleggaar FP,Siersema PD,van Oijen MG,Ten Kate FJ

    更新日期:2012-03-01 00:00:00

  • Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease.

    abstract::Crohn's disease is an idiopathic, chronic inflammatory disorder of the digestive tract with heterogeneous clinical presentations. Crohn's is currently not a curable disease, and patients are faced with a lifetime of recurrent disease flare-ups and remissions. Management strategies for Crohn's must therefore be targete...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/00054725-200407002-00002

    authors: Lichtenstein GR,Hanauer SB,Kane SV,Present DH

    更新日期:2004-07-01 00:00:00

  • IBD Systems Biology Is Here to Stay.

    abstract:BACKGROUND:Systems biology is a rapidly advancing field of science that allows us to look into disease mechanisms, patient diagnosis and stratification, and drug development in a completely new light. It is based on the utilization of unbiased computational systems free of the traditional experimental approaches based ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izaa343

    authors: Fiocchi C,Iliopoulos D

    更新日期:2021-01-13 00:00:00

  • Providing disease-related information worsens health-related quality of life in inflammatory bowel disease.

    abstract:BACKGROUND:Patients with inflammatory bowel disease (IBD) have identified a need for more information about their disease. PURPOSE:To assess the effect of an educational intervention on health-related quality of life (HRQOL) in patients with IBD. METHODS:Consecutive ambulatory IBD patients were randomized to receive ...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00054725-200207000-00005

    authors: Borgaonkar MR,Townson G,Donnelly M,Irvine EJ

    更新日期:2002-07-01 00:00:00

  • CARD15 and IL23R influences Crohn's disease susceptibility but not disease phenotype in a Brazilian population.

    abstract:BACKGROUND:Although many genetic variants are identified in association with Crohn's disease (CD), CARD15, IL23R, and ATG16L1 association with CD have been firmly confirmed in Caucasians of European ancestry. The prevalence of CD is rapidly rising in Brazil, where European ancestry is firmly admixed with natives and Af...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20372

    authors: Baptista ML,Amarante H,Picheth G,Sdepanian VL,Peterson N,Babasukumar U,Lima HC,Kugathasan S

    更新日期:2008-05-01 00:00:00

  • Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD: A Population-Based Analysis.

    abstract:INTRODUCTION:Antitumor necrosis factor (anti-TNF) medications are known to be highly efficacious in persons with moderate-to-severe inflammatory bowel disease (IBD). There is a paucity of data from population-based sources to elucidate persistence with these medications in the general population of IBD. Discontinuation...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000001025

    authors: Targownik LE,Tennakoon A,Leung S,Lix LM,Nugent Z,Singh H,Bernstein CN

    更新日期:2017-03-01 00:00:00

  • Sarcopenia and Inflammatory Bowel Disease: A Systematic Review.

    abstract:Background:Sarcopenia is associated with increased morbidity and mortality in oncologic and transplant surgery. It has a high incidence in chronic inflammatory states including inflammatory bowel disease (IBD). The validity of existing data in IBD and of sarcopenia's correlation with surgical outcomes is limited. Meth...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy212

    authors: Ryan E,McNicholas D,Creavin B,Kelly ME,Walsh T,Beddy D

    更新日期:2019-01-01 00:00:00

  • A genome-wide search identifies potential new susceptibility loci for Crohn's disease.

    abstract::Chronic inflammatory bowel disease (IBD) presents as two major clinical forms, Crohn's disease (CD) and ulcerative colitis (UC). Genetic epidemiological studies and animal models suggest that inherited factors play significant roles in the susceptibility to both forms of IBD. From four genome-wide scans, putative susc...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/00054725-199911000-00005

    authors: Ma Y,Ohmen JD,Li Z,Bentley LG,McElree C,Pressman S,Targan SR,Fischel-Ghodsian N,Rotter JI,Yang H

    更新日期:1999-11-01 00:00:00

  • Human β-defensin 3 peptide is increased and redistributed in Crohn's ileitis.

    abstract:BACKGROUND:Antimicrobial peptides (AMPs) maintain a sterile environment in intestinal crypts, limiting microbial colonization and invasion. Decreased AMP expression is proposed to increase the risk for inflammatory bowel disease. Expression and function of inducible AMPs, human β-defensin 2 and 3 (hBD-2 and hBD-3), rem...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0b013e318280b11a

    authors: Meisch JP,Nishimura M,Vogel RM,Sung HC,Bednarchik BA,Ghosh SK,Fu P,McCormick T,Weinberg A,Levine AD

    更新日期:2013-04-01 00:00:00

  • Portomesenteric vein thrombosis in patients with inflammatory bowel disease.

    abstract:BACKGROUND:Inflammatory bowel disease (IBD) is associated with a high risk of deep venous thromboembolism. However, few data are available so far on portomesenteric vein thrombosis (PMVT). The aim of this study was to describe the characteristics of PMVT in patients with IBD. METHODS:A retrospective study was conducte...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1097/MIB.0b013e31827eea5f

    authors: Landman C,Nahon S,Cosnes J,Bouhnik Y,Brixi-Benmansour H,Bouguen G,Colombel JF,Savoye G,Coffin B,Abitbol V,Filippi J,Laharie D,Moreau J,Veyrac M,Allez M,Marteau P,Groupe d'Etude Thérapeutique des Affections Inflammatoires

    更新日期:2013-03-01 00:00:00

  • Onset of Ulcerative Colitis in a Patient with Nonalcoholic Fatty Liver Disease (NAFLD): Dramatic Effect of Plant-based Diet for NAFLD.

    abstract::Nonalcoholic fatty liver disease (NAFLD) develops in ulcerative colitis (UC) and Crohn's disease. However, there is scarce reporting on the onset of UC in patients with NAFLD. A 44-year-old man was diagnosed with UC and referred to us in 2019. His height was 166.0 cm, and body weight was 86.3 kg. The waist circumferen...

    journal_title:Inflammatory bowel diseases

    pub_type: 信件

    doi:10.1093/ibd/izz208

    authors: Chiba M,Nakane K,Abe H,Komatsu M,Tozawa H

    更新日期:2019-10-18 00:00:00

  • Decreasing Colectomy Rate for Ulcerative Colitis in the United States Between 2007 and 2016: A Time Trend Analysis.

    abstract:BACKGROUND:Improved treatment approaches for ulcerative colitis (UC), including novel medications, might reduce the need for colectomy. We performed a retrospective cohort study of adult patients (age 18-64) with UC in the United States to examine time trends for colectomy and biologic use from 2007 to 2016. METHODS:W...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izz247

    authors: Barnes EL,Jiang Y,Kappelman MD,Long MD,Sandler RS,Kinlaw AC,Herfarth HH

    更新日期:2020-07-17 00:00:00

  • Therapy with anti-TNFα antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases.

    abstract:BACKGROUND:Inflammatory bowel diseases (IBDs) are associated with up-regulation of TNFα, hyperactivation of proinflammatory effector T cells (Teffs) and inefficient control by regulatory CD4(+) CD25(+) Foxp3(+) T cells (Tregs). The aim of this prospective study was to investigate the short-term impact of treatment of I...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21308

    authors: Boschetti G,Nancey S,Sardi F,Roblin X,Flourié B,Kaiserlian D

    更新日期:2011-01-01 00:00:00